STPG3-AS1: A Drug Target / Disease Biomarker (G100129722)

Target Name: STPG3-AS1

NCBI ID: G100129722

STPG3-AS1

Other Name(s): C9orf173-AS1 | STPG3 antisense RNA 1

STPG3-AS1: A Drug Target / Disease Biomarker

STPG3-AS1 is a protein that is expressed in the brain and is involved in the regulation of synaptic plasticity, which is the ability of the brain to change and adapt over time. The protein is found in the postsynaptic density, which is the layer of nerve cells that connect with each other in the brain.

Recent studies have suggested that STPG3-AS1 may be a drug target or biomarker for various neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, and depression. This is because the protein is involved in the regulation of important signaling pathways in the brain, and changes in the levels of STPG3-AS1 have been observed in these conditions.

One of the potential benefits of targeting STPG3-AS1 is that it has been shown to play a role in the development and progression of neurological disorders. For example, studies have shown that individuals with Alzheimer's disease have lower levels of STPG3-AS1 than healthy individuals, and that this may contribute to the progression of the disease. Similarly, STPG3-AS1 has been shown to be involved in the development of Parkinson's disease, and that lower levels of the protein may be associated with the progression of this condition.

In addition to its potential role in the development of neurological disorders, STPG3-AS1 is also a potential biomarker for these conditions. This is because the protein is often used as a target for drugs that are being developed for these disorders. For example, studies have shown that STPG3-AS1 is often targeted by drugs that are being developed for Alzheimer's disease, and that this may indicate that the protein is a useful biomarker for this condition.

Another potential application of STPG3-AS1 is its potential as a therapeutic target for depression. Studies have shown that STPG3-AS1 is involved in the regulation of the brain's response to stress, and that changes in the level of the protein may be associated with the development of depression. Additionally, STPG3-AS1 has been shown to play a role in the regulation of brain-derived neurotrophic factor (BDNF), which is a protein that is involved in the survival and growth of brain cells. This suggests that changes in the level of STPG3-AS1 may be involved in the development and progression of depression.

In conclusion, STPG3-AS1 is a protein that is expressed in the brain and is involved in the regulation of synaptic plasticity. The protein has been suggested as a potential drug target or biomarker for a variety of neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, and depression. Further research is needed to fully understand the role of STPG3-AS1 in these conditions, and to determine the best way to use it as a therapeutic target.

Protein Name: STPG3 Antisense RNA 1

The "STPG3-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about STPG3-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets